Gilead to develop second-generation protease inhibitor
January 15 2004 1:00 AM ET
Gilead Sciences filed an investigational new drug application Tuesday with the Food and Drug Administration to develop GS 9005, a once-daily protease inhibitor with a drug-resistance profile significantly different from those of existing protease inhibitors, The Wall Street Journal reports. Because of the drug's unique resistance profile, it could be effective for patients who've developed resistance to all other protease medications, company officials say. Gilead plans to begin early human tests later this year.